

IWILFIN is a prescription medicine used to reduce the risk of relapse in adults and children with high-risk neuroblastoma (HRNB) who have had at least a partial response to certain prior therapies.

Talking to Your Child's Doctor About How IWILFIN Can Help Reduce the Risk of a High-Risk Neuroblastoma Relapse

Whether your child has completed, or will soon complete, upfront treatment for high-risk neuroblastoma, now is the time to consider treatment options to help keep neuroblastoma at bay.

Below are some questions to consider asking your child's doctor about high-risk neuroblastoma and IWILFIN to better understand if IWILFIN may be an option for your child.

IWILFIN provides an alternative to watchful waiting, by allowing you to take an active role in protecting your child against relapse.

IWILFIN maintenance therapy after upfront treatment may help to maintain your child's response, prolong the period of remission, and increase overall survival chances.

Questions to Ask About High-Risk Neuroblastoma

- 1 What are my child's chances of a neuroblastoma relapse?
- 2 What will happen if my child relapses?
- 3 What is maintenance therapy?

Questions to Ask About IWILFIN

- 1 When would IWILFIN be an option for my child?
- 2 How does IWILFIN work?
- 3 How is IWILFIN taken?
- 4 What are some of IWILFIN's side effects I should know about?

What Is IWILFIN?

IWILFIN is a prescription medicine used to reduce the risk of relapse in adults and children with high-risk neuroblastoma (HRNB) who have had at least a partial response to certain prior therapies.

Important Safety Information

Before you take IWILFIN, tell your healthcare provider about your medical conditions, including if you have hearing problems, if you are pregnant or may become pregnant, or if you are breastfeeding.

If you or your partner are able to become pregnant, use effective birth control during treatment with IWILFIN and for 1 week after the last dose. Tell your healthcare provider right away if you or your partner become pregnant during treatment. Do not breastfeed during treatment with IWILFIN and for 1 week after the last dose.

Please see additional Important Safety Information on back.

